BNR vs EFAD
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BNR is a Hold and EFAD is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BNR’s FA Score shows that 1 FA rating(s) are green while.
- BNR’s FA Score: 1 green, 4 red.
Price Growth
BNR (@Medical Specialties) experienced а -7.73% price change this weekfor the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was +1.59%. For the same industry, the average monthly price growth was -9.77%, and the average quarterly price growth was -5.36%.
Reported Earning Dates
BNR is expected to report earnings on Aug 28, 2024.
Industries' Descriptions
@Medical Specialties (+1.59% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| EFAD | |
|---|---|
| RSI ODDS (%) | 2 days ago 86% |
| Stochastic ODDS (%) | 2 days ago 70% |
| Momentum ODDS (%) | 2 days ago 82% |
| MACD ODDS (%) | 2 days ago 81% |
| TrendWeek ODDS (%) | 2 days ago 80% |
| TrendMonth ODDS (%) | 2 days ago 76% |
| Advances ODDS (%) | 4 days ago 81% |
| Declines ODDS (%) | 12 days ago 76% |
| BollingerBands ODDS (%) | 2 days ago 89% |
| Aroon ODDS (%) | 2 days ago 74% |
EFAD and
Correlation & Price change
A.I.dvisor indicates that over the last year, EFAD has been loosely correlated with LOGI. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if EFAD jumps, then LOGI could also see price increases.
| Ticker / NAME | Correlation To EFAD | 1D Price Change % | ||
|---|---|---|---|---|
| EFAD | 100% | +0.76% | ||
| LOGI - EFAD | 52% Loosely correlated | +2.14% | ||
| BNR - EFAD | 12% Poorly correlated | -3.45% | ||
| UCB - EFAD | 8% Poorly correlated | +0.57% | ||
| ROG - EFAD | 7% Poorly correlated | +2.33% | ||
| APA - EFAD | 6% Poorly correlated | +4.81% | ||
More | ||||